Maze Therapeutics (MAZE) Free Cash Flow (2024 - 2026)
Maze Therapeutics recorded quarterly Free Cash Flow of -$39.1 million in Q1 2026, down 45.02% quarter-over-quarter from -$27.0 million in Q4 2025, and down 31.21% year-over-year from -$56.9 million in Q1 2025.
Maze Therapeutics' Free Cash Flow history runs 3 years deep, the most recent figure standing at -$39.1 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 31.21% year-over-year to -$39.1 million; the TTM figure through Mar 2026 stood at -$121.2 million (down 277.07% YoY), while the FY2025 annual figure was -$111.9 million, down 249.65% from the prior year.
- Free Cash Flow came in at -$39.1 million for Q1 2026 at Maze Therapeutics, down from -$27.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $144.7 million in Q2 2024 to a low of -$39.1 million in Q1 2026.
- A 3-year average of -$8.5 million and a median of -$24.7 million in 2025 frame the typical range for Free Cash Flow.
- On a YoY basis, Free Cash Flow climbed as much as 6.02% in 2025 and fell as far as 121.05% in 2025.
- Maze Therapeutics' Free Cash Flow stood at -$23.1 million in 2024, then decreased by 16.99% to -$27.0 million in 2025, then slumped by 45.02% to -$39.1 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$39.1 million, -$27.0 million, and -$24.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | -39.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.12 Mn |
| Mar 31, 2026 | -39.12 Mn |
| Dec 31, 2025 | -26.98 Mn |
| Dec 31, 2025 | -26.98 Mn |
| Sep 30, 2025 | -24.71 Mn |
| Sep 30, 2025 | -24.71 Mn |
| Jun 30, 2025 | -30.45 Mn |
| Jun 30, 2025 | -30.45 Mn |
| Mar 31, 2025 | -29.82 Mn |
| Mar 31, 2025 | -29.82 Mn |
| Dec 31, 2024 | -23.06 Mn |
| Dec 31, 2024 | -23.06 Mn |
| Sep 30, 2024 | -23.31 Mn |
| Sep 30, 2024 | -23.31 Mn |
| Jun 30, 2024 | 144.66 Mn |
| Jun 30, 2024 | 144.66 Mn |
| Mar 31, 2024 | -23.48 Mn |
| Mar 31, 2024 | -23.48 Mn |